[HTML][HTML] Poly (lactic acid)-based microparticles for drug delivery applications: An overview of recent advances
A Vlachopoulos, G Karlioti, E Balla, V Daniilidis… - Pharmaceutics, 2022 - mdpi.com
The sustained release of pharmaceutical substances remains the most convenient way of
drug delivery. Hence, a great variety of reports can be traced in the open literature …
drug delivery. Hence, a great variety of reports can be traced in the open literature …
Advances in controlled release pesticide formulations: Prospects to safer integrated pest management and sustainable agriculture
As the world is striving hard towards sustainable agricultural practices for a better tomorrow,
one of the primary focuses is on effective pest management for enhanced crop productivity …
one of the primary focuses is on effective pest management for enhanced crop productivity …
A Review of In Vitro Drug Release Test Methods for Nano‐Sized Dosage Forms
S D'Souza - Advances in pharmaceutics, 2014 - Wiley Online Library
This review summarizes the methods used to study real‐time (37° C) drug release from
nanoparticulate drug delivery systems and establish an IVIVC. Since no compendial …
nanoparticulate drug delivery systems and establish an IVIVC. Since no compendial …
The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems—A review
S Fredenberg, M Wahlgren, M Reslow… - International journal of …, 2011 - Elsevier
Abstract Poly (d, l-lactic-co-glycolic acid)(PLGA) is the most frequently used biodegradable
polymer in the controlled release of encapsulated drugs. Understanding the release …
polymer in the controlled release of encapsulated drugs. Understanding the release …
PLGA-based nanoparticles as cancer drug delivery systems
FS Tabatabaei Mirakabad, K Nejati-Koshki… - Asian Pacific Journal …, 2014 - koreascience.kr
Poly (lactic-co-glycolic acid)(PLGA) is one of the most effective biodegradable polymeric
nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems …
nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems …
[HTML][HTML] Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects
Controlled release delivery is available for many routes of administration and offers many
advantages (as microparticles and nanoparticles) over immediate release delivery. These …
advantages (as microparticles and nanoparticles) over immediate release delivery. These …
Intra‐articular depot formulation principles: Role in the management of postoperative pain and arthritic disorders
C Larsen, J Østergaard, SW Larsen, H Jensen… - Journal of …, 2008 - Elsevier
The joint cavity constitutes a discrete anatomical compartment that allows for local drug
action after intra‐articular injection. Drug delivery systems providing local prolonged drug …
action after intra‐articular injection. Drug delivery systems providing local prolonged drug …
Methods to Assess in Vitro Drug Release from Injectable Polymeric Particulate Systems
SS D'Souza, PP DeLuca - Pharmaceutical research, 2006 - Springer
This review provides a compilation of the methods used to study real-time (37° C) drug
release from parenteral microparticulate drug delivery systems administered via the …
release from parenteral microparticulate drug delivery systems administered via the …
[HTML][HTML] Recent progress in drug release testing methods of biopolymeric particulate system
Y Kim, EJ Park, TW Kim, DH Na - Pharmaceutics, 2021 - mdpi.com
Biopolymeric microparticles have been widely used for long-term release formulations of
short half-life chemicals or synthetic peptides. Characterization of the drug release from …
short half-life chemicals or synthetic peptides. Characterization of the drug release from …
[HTML][HTML] Weibull modeling of controlled drug release from Ag-PMA Nanosystems
Traditional pharmacotherapy suffers from multiple drawbacks that hamper patient treatment
such as antibiotic resistances or low drug selectivity and toxicity during systemic …
such as antibiotic resistances or low drug selectivity and toxicity during systemic …